NCT01419470

Safety, Tolerability, Pharmacokinetics and Efficacy of YHD1044

Phase Ⅰ/Ⅱ Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of YHD1044 After Oral Administration in Premature Ejaculation Patients

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Yuhan Corporation · Industry
• Sex: Male
• Age: 20 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

safety and tolerability, pharmacokinetics/efficacy of an escalating, repeat doses of YHD1044 in premature ejaculation

Conditions

• Premature Ejaculation

Interventions

Type	Name	Description
DRUG	dapoxetine	1. multiple dosing 2. 12 subjects will be administered YHD1044 (I, III, V) or active/placebo comparators;dapoxetine

Timeline

• Start date: 2011-02-01
• Primary completion: 2012-05-01
• Completion: 2012-05-01
• First posted: 2011-08-18
• Last updated: 2012-08-01

Locations

1 site across 1 country: South Korea